Mazdutide
Maz · GLP-1/GCG
GLP-1/glucagon dual agonist; long half-life, weekly dosing.
Key takeaways
- Dual GLP-1/glucagon agonist; approved in China, investigational everywhere else.
- GLORY-1 phase 3: 12.6% weight loss at 32 weeks on 6 mg, 14.0% by 48 weeks.
- Modeled ~18-day half-life is a geometric mean of a wide 7–45 day reported range.
- Evidence is nearly all Chinese-population data; long-term outcomes still accumulating.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Obesity (GLORY-1 trial) | Escalated to 4 or 6 mg | SubQ | Once weekly | 48 weeks |
Pharmacokinetic summary
- Model tier
- Advanced (t½ + Cmax + Tmax + F)
- Half-life
- 18 days
- Cmax
- 7348.3333 nmol/L
- Tmax
- 3.0 days
- Bioavailability
- 80%
- Typical dose
- 3–9 mg
Frequently asked questions
Is mazdutide available outside China?
Not through approved channels. It holds Chinese approvals for weight management and glycemic control, while global phase 3 programs are still running. Anything sold elsewhere is unregulated grey-market peptide.
How does mazdutide compare to semaglutide?
Mazdutide adds glucagon receptor activity, which increases energy expenditure and hepatic fat oxidation. Cross-trial weight-loss numbers land between semaglutide and tirzepatide, but no large head-to-head trial against them has been published yet.
What side effects dominate?
Gastrointestinal, as with the rest of the incretin class: nausea, vomiting, and diarrhea, mostly mild to moderate and concentrated in the escalation phase. Discontinuation for adverse events was low in GLORY-1.
References
- PMC mazdutide PK — Half-life range 7.3–44.8 days; geometric mean used.
- Ji et al., NEJM 2025 — GLORY-1 phase 3 — Once-weekly mazdutide in Chinese adults with obesity or overweight.
- Mazdutide phase 1b PK/efficacy (EClinicalMedicine 2022) — Entry's PK source; half-life estimates span 7.3–44.8 days.
Related compounds
Survodutide
Investigational dual GLP-1/glucagon receptor agonist for obesity and MASH; weekly injection.
Semaglutide Injection (Ozempic/Wegovy)
Long-acting GLP-1 receptor agonist for type 2 diabetes and weight loss; weekly injection.
Semaglutide Oral (Rybelsus)
Oral semaglutide with very low bioavailability; taken fasting.
Comments
Loading comments…